Consolidated Balance Sheets - USD ($) $ in Millions		Dec. 31, 2019	Dec. 31, 2018
Assets
Cash and cash equivalents		$ 4,619	$ 3,855
Investments		937	2,045
Accounts receivable, net		10,716	10,473
Inventories		2,661	2,821
Other current assets		1,400	1,236
Assets of business held for sale		9,512	0
Total current assets		29,845	20,430
Long-term investments		21,542	26,929
Reinsurance recoverables		5,100	5,507
Deferred policy acquisition costs		2,958	2,821
Property and equipment		4,417	4,562
Goodwill		44,602	44,505
Other intangible assets		36,562	39,003
Other assets		2,283	1,630
Separate account assets		8,465	7,839
TOTAL ASSETS		155,774	153,226
Liabilities:
Current insurance and contractholder liabilities		4,921	6,801
Pharmacy and service costs payable		10,454	10,702
Accounts payable		5,090	4,366
Accrued expenses and other liabilities		7,347	7,071
Short-term debt		5,514	2,955
Liabilities of business held for sale		6,812	0
Total current liabilities		40,138	31,895
Non-current insurance and contractholder liabilities		16,052	19,974
Deferred tax liabilities, net		9,387	9,453
Other non-current liabilities		4,460	3,470
Long-term debt		31,893	39,523
Separate account liabilities		8,465	7,839
TOTAL LIABILITIES		110,395	112,154
Contingencies - Note 22
Redeemable noncontrolling interests		35	37
Shareholders' Equity
Common stock	[1]	4	4
Additional paid-in capital		28,306	27,751
Accumulated other comprehensive income (loss)		(941)	(1,711)
Retained earnings		20,162	15,088
Less: treasury stock, at cost		(2,193)	(104)
TOTAL SHAREHOLDERS' EQUITY		45,338	41,028
Other noncontrolling interests		6	7
Total equity		45,344	41,035
Total liabilities and shareholders' equity		$ 155,774	$ 153,226

[1] Par value per share, $0.01; shares issued, 386 million as of December 31, 2019 and 381 million as of December 31, 2018; authorized shares; 600 million.